Skye Bioscience (SKYE) Other Non-Current Liabilities (2014 - 2022)
Skye Bioscience (SKYE) posted quarterly Other Non-Current Liabilities of $326.0 for Q3 2022, down 99.84% year-over-year from $207916.0 in Q3 2021, and down 95.03% quarter-over-quarter from $6554.0 in Q2 2022.
Skye Bioscience (SKYE) Other Non-Current Liabilities (2014 - 2022) Analysis & Trends
Skye Bioscience (SKYE) has reported Other Non-Current Liabilities for 9 consecutive years, with $326.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Other Non-Current Liabilities fell 99.84% year-over-year to $326.0; the TTM figure through Sep 2022 stood at $326.0 (down 99.84% YoY), while the FY2021 annual figure was $59732.0, up 54.88% from the prior year.
- Other Non-Current Liabilities retreated to $326.0 in Q3 2022 per SKYE's latest filing, from $6554.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $14.3 million in Q3 2019 and bottomed at $326.0 in Q3 2022.
- Historically, Other Non-Current Liabilities has averaged $3.1 million across 5 years, with a median of $397565.0 in 2021.
- Annual changes were most pronounced in 2018 — Other Non-Current Liabilities surged 1030.37% — and 2022, when it slumped 99.84%.
- Skye Bioscience's Other Non-Current Liabilities stood at $219453.0 in 2018, then surged by 128.48% to $501400.0 in 2019, then plunged by 92.31% to $38567.0 in 2020, then jumped by 54.88% to $59732.0 in 2021, then slumped by 99.45% to $326.0 in 2022.
- Business Quant data shows SKYE's Other Non-Current Liabilities at $326.0 in Q3 2022, $6554.0 in Q2 2022, and $16077.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - |
| 10 | Skye Bioscience | 10.66 Mn | 10.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 326.00 |
| Jun 30, 2022 | 6,554.00 |
| Mar 31, 2022 | 16,077.00 |
| Dec 31, 2021 | 59,732.00 |
| Sep 30, 2021 | 207,916.00 |
| Jun 30, 2021 | 397,565.00 |
| Mar 31, 2021 | 276,917.00 |
| Dec 31, 2020 | 38,567.00 |
| Sep 30, 2020 | 41,149.00 |
| Jun 30, 2020 | 465,287.00 |
| Mar 31, 2020 | 438,934.00 |
| Dec 31, 2019 | 501,400.00 |
| Sep 30, 2019 | 14.31 Mn |
| Jun 30, 2019 | 11.18 Mn |
| Mar 31, 2019 | 963,369.00 |
| Dec 31, 2018 | 219,453.00 |
| Sep 30, 2018 | 11.11 Mn |
| Jun 30, 2018 | 10.09 Mn |
| Mar 31, 2018 | 8.59 Mn |
| Dec 31, 2017 | 551,322.00 |